Tudor Investment Corp ET AL Purchases Shares of 21,705 Global Blood Therapeutics, Inc. (NASDAQ:GBT)

Tudor Investment Corp ET AL purchased a new position in Global Blood Therapeutics, Inc. (NASDAQ:GBT) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 21,705 shares of the company’s stock, valued at approximately $594,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of GBT. FMR LLC raised its stake in Global Blood Therapeutics by 2.9% during the first quarter. FMR LLC now owns 5,759,471 shares of the company’s stock valued at $212,236,000 after purchasing an additional 162,004 shares in the last quarter. Perceptive Advisors LLC raised its stake in Global Blood Therapeutics by 23.3% during the first quarter. Perceptive Advisors LLC now owns 3,858,978 shares of the company’s stock valued at $142,203,000 after purchasing an additional 730,000 shares in the last quarter. BlackRock Inc. raised its stake in Global Blood Therapeutics by 30.0% during the second quarter. BlackRock Inc. now owns 3,404,538 shares of the company’s stock valued at $93,114,000 after purchasing an additional 785,691 shares in the last quarter. Vanguard Group Inc. raised its stake in Global Blood Therapeutics by 15.7% during the second quarter. Vanguard Group Inc. now owns 2,933,251 shares of the company’s stock valued at $80,224,000 after purchasing an additional 397,271 shares in the last quarter. Finally, Wellington Management Group LLP raised its stake in Global Blood Therapeutics by 10.8% during the first quarter. Wellington Management Group LLP now owns 2,321,123 shares of the company’s stock valued at $85,534,000 after purchasing an additional 225,994 shares in the last quarter. Institutional investors and hedge funds own 86.07% of the company’s stock.

In related news, Director Deval L. Patrick sold 27,053 shares of the firm’s stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $29.69, for a total transaction of $803,203.57. Following the sale, the director now owns 12,053 shares of the company’s stock, valued at approximately $357,853.57. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Jung Choi sold 3,000 shares of Global Blood Therapeutics stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $30.00, for a total value of $90,000.00. Following the completion of the sale, the insider now directly owns 141,655 shares in the company, valued at approximately $4,249,650. The disclosure for this sale can be found here. Insiders sold a total of 36,053 shares of company stock worth $1,073,204 over the last quarter. Corporate insiders own 5.30% of the company’s stock.

Several equities research analysts have recently weighed in on the stock. BidaskClub downgraded shares of Global Blood Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, July 19th. Zacks Investment Research upgraded shares of Global Blood Therapeutics from a “hold” rating to a “buy” rating and set a $36.00 price target on the stock in a report on Tuesday, October 10th. Needham & Company LLC started coverage on shares of Global Blood Therapeutics in a report on Wednesday, September 20th. They issued a “buy” rating and a $51.00 price target on the stock. Oppenheimer Holdings, Inc. assumed coverage on shares of Global Blood Therapeutics in a report on Friday, August 4th. They set an “outperform” rating and a $53.00 target price on the stock. Finally, Morgan Stanley restated an “overweight” rating and issued a $56.00 price target (up from $51.00) on shares of Global Blood Therapeutics in a report on Friday, October 6th. Three investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $54.08.

Global Blood Therapeutics, Inc. (GBT) traded down 1.82% during midday trading on Wednesday, hitting $32.30. The stock had a trading volume of 226,141 shares. The company has a 50-day moving average price of $29.44 and a 200-day moving average price of $29.29. The company’s market cap is $1.41 billion. Global Blood Therapeutics, Inc. has a 12-month low of $13.35 and a 12-month high of $41.15.

Global Blood Therapeutics (NASDAQ:GBT) last released its quarterly earnings data on Monday, August 7th. The company reported ($0.55) earnings per share for the quarter, beating the consensus estimate of ($0.61) by $0.06. During the same period in the prior year, the business earned ($0.58) earnings per share. Equities analysts anticipate that Global Blood Therapeutics, Inc. will post ($2.44) EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by BBNS and is the sole property of of BBNS. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this piece of content can be accessed at https://baseballnewssource.com/markets/21705-shares-in-global-blood-therapeutics-inc-gbt-acquired-by-tudor-investment-corp-et-al/1701928.html.

Global Blood Therapeutics Company Profile

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Institutional Ownership by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Houston’s Dallas Keuchel Could Make Relief Appearance in Game 7
Houston’s Dallas Keuchel Could Make Relief Appearance in Game 7
Houston Astros Relying on Justin Verlander to Save Their Season
Houston Astros Relying on Justin Verlander to Save Their Season
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Aaron Judge and Gary Sanchez Have Break Out Games
Aaron Judge and Gary Sanchez Have Break Out Games
Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation


Leave a Reply

 
© 2006-2017 BBNS.